Preliminary results suggest combination therapy with lisaftoclax improves survival with few adverse events in patients with AL amyloidosis and relapsed/refractory multiple myeloma
Early results show patients experiencing deep and complete response
Multi-specialty coordination essential for improving quality of life
On-demand stem cell mobilizer is an effective salvage strategy
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Follow-up study confirms safety and tolerability of new treatment protocol
Study associates human CD38-targeting antibody with fewer complications
Advertisement
Advertisement